286 related articles for article (PubMed ID: 28302541)
1. Trends on Analytical Characterization of Polysorbates and Their Degradation Products in Biopharmaceutical Formulations.
Martos A; Koch W; Jiskoot W; Wuchner K; Winter G; Friess W; Hawe A
J Pharm Sci; 2017 Jul; 106(7):1722-1735. PubMed ID: 28302541
[TBL] [Abstract][Full Text] [Related]
2. How enzymatic hydrolysis of polysorbate 20 influences colloidal protein stability.
Glücklich N; Carle S; Diederichs T; Buske J; Mäder K; Garidel P
Eur J Pharm Sci; 2023 Dec; 191():106597. PubMed ID: 37770006
[TBL] [Abstract][Full Text] [Related]
3. Polysorbates versus Hydroxypropyl Beta-Cyclodextrin (HPβCD): Comparative Study on Excipient Stability and Stabilization Benefits on Monoclonal Antibodies.
Zhang H; Hong S; Tan SSK; Peng T; Goh LYH; Lam KH; Chow KT; Gokhale R
Molecules; 2022 Oct; 27(19):. PubMed ID: 36235038
[TBL] [Abstract][Full Text] [Related]
4. A Newly Identified Impurity in Polysorbate 80, the Long-Chain Ketone 12-Tricosanone, Forms Visible Particles in a Biopharmaceutical Drug Product.
Hampl V; Guo X; Ehrenstrasser C; Viertler M; Rayner L; Campanelli G; Schipflinger R; Thewes K; Cerreti A; Boehm S; Sonderegger C
J Pharm Sci; 2018 Jun; 107(6):1552-1561. PubMed ID: 29499279
[TBL] [Abstract][Full Text] [Related]
5. Quantitation of low concentrations of polysorbates in high protein concentration formulations by solid phase extraction and cobalt-thiocyanate derivatization.
Kim J; Qiu J
Anal Chim Acta; 2014 Jan; 806():144-51. PubMed ID: 24331050
[TBL] [Abstract][Full Text] [Related]
6. Characterization of Polysorbate Ester Fractions and Implications in Protein Drug Product Stability.
Tomlinson A; Zarraga IE; Demeule B
Mol Pharm; 2020 Jul; 17(7):2345-2353. PubMed ID: 32442382
[TBL] [Abstract][Full Text] [Related]
7. Considerations for the Use of Polysorbates in Biopharmaceuticals.
Jones MT; Mahler HC; Yadav S; Bindra D; Corvari V; Fesinmeyer RM; Gupta K; Harmon AM; Hinds KD; Koulov A; Liu W; Maloney K; Wang J; Yeh PY; Singh SK
Pharm Res; 2018 May; 35(8):148. PubMed ID: 29797101
[TBL] [Abstract][Full Text] [Related]
8. Novel High-Throughput Assay for Polysorbate Quantification in Biopharmaceutical Products by Using the Fluorescent Dye DiI.
Martos A; Berger M; Kranz W; Spanopoulou A; Menzen T; Friess W; Wuchner K; Hawe A
J Pharm Sci; 2020 Jan; 109(1):646-655. PubMed ID: 31606542
[TBL] [Abstract][Full Text] [Related]
9. The degradation of polysorbates 20 and 80 and its potential impact on the stability of biotherapeutics.
Kishore RS; Kiese S; Fischer S; Pappenberger A; Grauschopf U; Mahler HC
Pharm Res; 2011 May; 28(5):1194-210. PubMed ID: 21369824
[TBL] [Abstract][Full Text] [Related]
10. Polysorbates 20 and 80 used in the formulation of protein biotherapeutics: structure and degradation pathways.
Kerwin BA
J Pharm Sci; 2008 Aug; 97(8):2924-35. PubMed ID: 17973307
[TBL] [Abstract][Full Text] [Related]
11. All-in-one stability indicating polysorbate 20 degradation root-cause analytics via UPLC-QDa.
Carle S; Evers DH; Hagelskamp E; Garidel P; Buske J
J Chromatogr B Analyt Technol Biomed Life Sci; 2024 Jan; 1232():123955. PubMed ID: 38128165
[TBL] [Abstract][Full Text] [Related]
12. Controlled polysorbate 20 hydrolysis - A new approach to assess the impact of polysorbate 20 degradation on biopharmaceutical product quality in shortened time.
Graf T; Abstiens K; Wedekind F; Elger C; Haindl M; Wurth C; Leiss M
Eur J Pharm Biopharm; 2020 Jul; 152():318-326. PubMed ID: 32445968
[TBL] [Abstract][Full Text] [Related]
13. Poloxamer 188 as surfactant in biological formulations - An alternative for polysorbate 20/80?
Bollenbach L; Buske J; Mäder K; Garidel P
Int J Pharm; 2022 May; 620():121706. PubMed ID: 35367584
[TBL] [Abstract][Full Text] [Related]
14. Drug-excipient compatibility testing-Identification and characterization of degradation products of phenylephrine in several pharmaceutical formulations against the common cold.
Douša M; Gibala P; Havlíček J; Plaček L; Tkadlecová M; Břicháč J
J Pharm Biomed Anal; 2011 Jul; 55(5):949-56. PubMed ID: 21481557
[TBL] [Abstract][Full Text] [Related]
15. Analytical methods and formulation factors to enhance protein stability in solution.
Jeong SH
Arch Pharm Res; 2012 Nov; 35(11):1871-86. PubMed ID: 23212628
[TBL] [Abstract][Full Text] [Related]
16. Novel markers to track oxidative polysorbate degradation in pharmaceutical formulations.
Dahotre S; Tomlinson A; Lin B; Yadav S
J Pharm Biomed Anal; 2018 Aug; 157():201-207. PubMed ID: 29803911
[TBL] [Abstract][Full Text] [Related]
17. Reactive impurities in excipients: profiling, identification and mitigation of drug-excipient incompatibility.
Wu Y; Levons J; Narang AS; Raghavan K; Rao VM
AAPS PharmSciTech; 2011 Dec; 12(4):1248-63. PubMed ID: 21948318
[TBL] [Abstract][Full Text] [Related]
18. Brij-58, a potential injectable protein-stabilizer used in therapeutic protein formulation.
Yue L; Yan Z; Li H; Liu X; Sun P
Eur J Pharm Biopharm; 2020 Jan; 146():73-83. PubMed ID: 31811896
[TBL] [Abstract][Full Text] [Related]
19. Polysorbate 20 Degradation in Biopharmaceutical Formulations: Quantification of Free Fatty Acids, Characterization of Particulates, and Insights into the Degradation Mechanism.
Tomlinson A; Demeule B; Lin B; Yadav S
Mol Pharm; 2015 Nov; 12(11):3805-15. PubMed ID: 26419339
[TBL] [Abstract][Full Text] [Related]
20. Investigation of excipients impact on polysorbate 80 degradation in biopharmaceutical formulation buffers.
Bai L; Zhang Y; Zhang C; Lu Y; Li Z; Huang G; Meng B
J Pharm Biomed Anal; 2023 Sep; 233():115496. PubMed ID: 37285658
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
